QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

DMAA

QT55Drugs Made In America Acquisition Corp. Ordinary Shares
NASDAQ·Financial Services·Shell Companies·USA
Latest market price
10.63
+0.01+0.09%
OverviewShort InterestFilings
DMAAQT55Drugs Made In America Acquisition Corp. Ordinary Shares·NASDAQ
OverviewShort InterestFilings
10.63+0.09%
TA
Loading chart...
Screen all →
APXT+0.10%$10.06VACHU+0.00%$14.50UMAC+2.17%$24.98PWRL-5.66%$16.51CEPF+0.00%$10.38PONO+0.00%$10.00BCSS+0.00%$10.21ANSC+0.18%$11.42
Snapshot
Index-P/E36.69EPS (ttm)0.29
Insider Own-
Shs Outstand24.28M
Perf Week0.19%
Market Cap358.08MForward P/E-EPS next Y-Insider Trans-Shs Float-Perf Month0.47%
Enterprise Value358.16MPEG-EPS next Q-Inst Own-Short Float-Perf Quarter1.53%
Income9.78MP/S0.00EPS this Y-Inst Trans-Short Ratio-Perf Half Y2.61%
Sales-P/B1.04EPS next Y-ROA2.75%Short Interest-Perf YTD2.51%
Book/sh9.60P/C-EPS next 5Y-ROE2.88%52W High10.63 0.00%Perf Year4.32%
Cash/sh0.00P/FCF-EPS past 3/5Y-ROIC-1.09%52W Low10.17 4.52%Perf 3Y-
Dividend Est.-EV/EBITDA-136.27Sales past 3/5Y-Gross Margin0.00%Volatility0.08% 0.11%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM-Oper. Margin0.00%ATR (14)0.01Perf 10Y-
Dividend Ex-Date-Quick Ratio0.03Sales Y/Y TTM-Profit Margin0.00%RSI (14)66.46Recom-
Dividend Gr. 3/5Y-Current Ratio0.03EPS Q/Q-SMA200.19%Beta-0.00Target Price-
Payout0.00%Debt/Eq0.00Sales Q/Q-SMA500.46%Rel Volume0.13Prev Close10.62
Employees2LT Debt/Eq-Earnings-SMA2001.96%Avg Volume117.59KPrice10.63
IPO DateJan 27, 2025Option/ShortYes / YesEPS/Sales Surpr.-Net Debt/EBITDA-0.03Volume14,773Change0.09%
Latest News
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
Total Revenue
00
Cost of Goods Sold Incl. D&A
00
Gross Profit
00
Selling, General and Administrative Excl. Other30
Research and Development
00
Other Operating Expense
00
Operating Income-30
Interest Expense
00
Unusual Expense
——
Non-Operating Income (Expense)
00
Net Income Before Taxes60
Income Taxes
00
Consolidated Net Income60
Net Income From Continuing Operations60
Net Income60
EPS (Recurring)0.19-0.06
EPS (Basic, Before Extraordinaries)0.19-0.06
EPS (Diluted)0.19-0.06
EBITDA-30
Other After Tax Adjustments
——
Stock Option Compensation Expense
——
Price To Earnings Ratio54.58—
Price To Sales Ratio
——
Gross Margin
——
Operating Margin
——
Net Margin
——
Shares Outstanding219
Market Capitalization218—
Operating Lease Expense
——
Insider Trading Volume
$11.69$10.34$9.00$7.65$6.30● Close Price0.00K0.00K0.00K0.00K0.00KUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Drugs Made In America Acquisition LLC10% OwnerFeb 18 '25Buy0.0060,00004,188,780Feb 18 12:00 AM
Stockwell LynnCEO and Exe. Chair of BoardFeb 18 '25Buy0.0060,00004,188,780Feb 18 12:00 AM
Drugs Made In America Acquisition LLC10% OwnerJan 29 '25Buy0.00800,000010,257,143Feb 04 12:00 AM
Drugs Made In America Acquisition LLC10% OwnerJan 29 '25Sale1.505,698,3638,547,5454,158,780Feb 04 12:00 AM
Stockwell LynnCEO and Executive COBJan 29 '25Sale1.505,698,3638,547,5454,158,780Feb 04 12:00 AM
Stockwell LynnCEO and Executive COBJan 29 '25Buy0.00800,0000400,000Feb 04 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR